Supplementary material 5. Meta-analysis results of adverse drug reactions (Figures S25-34)

Study or Subgroup	Aidi injection Events	Total	Gemcitabine and cisplatin Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI
Cai,H.2013	5	19	8	19	2.9%	0.49 [0.13, 1.93]
Geng,K.2020	12	45	8	45	2.9%	1.68 [0.61, 4.62]
He,W.2011	9	29	17	23	6.4%	0.16 [0.05, 0.54]
Ju,S.2013	11	34	23	34	7.6%	0.23 [0.08, 0.63]
Lai,L.2013	25	70	31	70	9.8%	0.70 [0.35, 1.38]
Li,H.2014	16	30	21	30	4.8%	0.49 [0.17, 1.41]
Li,Z.2010	10	36	21	36	7.4%	0.27 [0.10, 0.74]
Liu,Y.2010	3	32	11	32	4.9%	0.20 [0.05, 0.80]
Lv,D.2009	16	30	24	30	5.5%	0.29 [0.09, 0.90]
Shi,X.2010	16	28	23	28	4.8%	0.29 [0.09, 0.98]
Song,Z.2009	7	30	12	30	4.5%	0.46 [0.15, 1.40]
Su,D.2019	4	41	13	41	5.8%	0.23 [0.07, 0.79]
Su, S.2017	2	40	3	39	1.4%	0.63 [0.10, 4.00]
Wen, H.2014	17	45	26	45	7.9%	0.44 [0.19, 1.03]
Xu,Y.2012	23	33	33	33		0.03 [0.00, 0.60]
Zhou, D.2018	12	58	34	58	13.2%	0.18 [0.08, 0.42]
Zou,Y.2006	30	42	34	39	4.9%	0.37 [0.12, 1.16]
Total (95% CI)		**642**		**632**	**100.0%**	**0.36 [0.28, 0.47]**
Total events	218		342			

Heterogeneity: Chi² = 23.27, df = 16 (P = 0.11); I² = 31%
Test for overall effect: Z = 7.83 (P < 0.00001)

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

Figure S25 The analysis of myelosuppression between the two groups

Study or Subgroup	Aidi injection Events	Total	Gemcitabine and cisplatin Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI	Year
Feng,X.2008	64	68	60	62	0.9%	0.53 [0.09, 3.02]	2008
Wang,Y.2009	26	32	22	27	1.0%	0.98 [0.26, 3.67]	2009
Wen,K.2009	23	38	31	38	2.8%	0.35 [0.12, 0.99]	2009
Zhang, L.2009	5	32	14	31	2.8%	0.22 [0.07, 0.74]	2009
Hong,Y.2010	26	90	31	70	5.7%	0.51 [0.27, 0.98]	2010
Hou,A.2010	14	40	22	38	3.4%	0.39 [0.16, 0.98]	2010
Lu,Z.2011	11	34	20	34	3.1%	0.33 [0.12, 0.90]	2011
Zhang,Y. 2012	12	41	17	42	2.7%	0.61 [0.24, 1.52]	2012
Xu,Y.2012	23	33	33	33	2.4%	0.03 [0.00, 0.60]	2012
Fu, L.2012	24	35	32	35	2.3%	0.20 [0.05, 0.81]	2012
Wang,J.2012	7	25	9	24	1.5%	0.65 [0.19, 2.16]	2012
Wang,Y.2012	19	36	26	36	2.8%	0.43 [0.16, 1.15]	2012
Sun,J.2012	23	34	30	34	2.2%	0.28 [0.08, 0.99]	2012
Xu, H.2013	13	38	22	42	3.2%	0.47 [0.19, 1.17]	2013
Cheng, B.2014	34	49	47	52	3.2%	0.24 [0.08, 0.73]	2014
Liu,Y.2014	27	43	36	43	3.1%	0.33 [0.12, 0.91]	2014
Li, J.2014	5	27	6	27	1.1%	0.80 [0.21, 3.00]	2014
Li, X.2015	2	20	8	20	1.7%	0.17 [0.03, 0.92]	2015
Zhao, S.2015	7	43	10	43	1.9%	0.64 [0.22, 1.88]	2015
Zhang, M.2015	26	39	28	32	2.4%	0.29 [0.08, 0.99]	2015
Ning, S.2015	16	31	16	31	1.8%	1.00 [0.37, 2.71]	2015
Zhu, H.2015	6	21	15	21	2.5%	0.16 [0.04, 0.61]	2015
Han, R.2015	7	36	11	36	2.0%	0.55 [0.18, 1.63]	2015
Li, J.-c.2016	14	35	26	35	3.6%	0.23 [0.08, 0.64]	2016
Ma, Y. 2016	7	33	15	35	2.7%	0.36 [0.12, 1.05]	2016
Fang, L.2016	5	45	13	45	2.7%	0.31 [0.10, 0.95]	2016
Li, J.2016	12	47	19	47	3.3%	0.51 [0.21, 1.21]	2016
Zhang, S.2016	2	19	4	19	0.8%	0.44 [0.07, 2.76]	2016
Zhang, H.2017	13	52	22	52	3.8%	0.45 [0.20, 1.05]	2017
Ma, M.2017	11	42	16	42	2.7%	0.58 [0.23, 1.46]	2017
Huang, W.2017	10	39	12	40	2.0%	0.80 [0.30, 2.16]	2017
Su, S.2017	2	40	2	39	0.4%	0.97 [0.13, 7.28]	2017
Wu, Y.2017	3	109	9	109	2.0%	0.31 [0.08, 1.19]	2017
Wu, T.2017	10	67	21	68	4.1%	0.39 [0.17, 0.92]	2017
Zhang, H.2018	13	30	22	30	2.9%	0.28 [0.09, 0.82]	2018
Zhou, D.2018	11	58	13	58	2.4%	0.81 [0.33, 1.99]	2018
Guo, X.2020	7	51	16	51	3.2%	0.35 [0.13, 0.94]	2020
Tan, H.2020	51	60	57	60	2.0%	0.30 [0.08, 1.16]	2020
Chen,C.2020	33	49	43	49	3.2%	0.29 [0.10, 0.82]	2020
Xu,Z.2020	2	40	6	40	1.3%	0.30 [0.06, 1.58]	2020
Total (95% CI)		**1701**		**1670**	**100.0%**	**0.41 [0.35, 0.49]**	
Total events	626		862				

Heterogeneity: Chi² = 26.97, df = 39 (P = 0.93); I² = 0%
Test for overall effect: Z = 10.32 (P < 0.00001)

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

Figure S26 The analysis of neutropenia between the two groups

Study or Subgroup	Aidi injection Events	Total	Gemcitabine and cisplatin Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI	Year
Feng,X.2008	62	68	62	62	2.4%	0.08 [0.00, 1.39]	2008
Zhang, L.2009	4	32	9	31	3.2%	0.35 [0.09, 1.29]	2009
Wang,Y.2009	4	32	2	27	0.8%	1.79 [0.30, 10.60]	2009
Wen,K.2009	22	38	24	38	4.0%	0.80 [0.32, 2.02]	2009
Hou,A.2010	3	40	8	38	3.0%	0.30 [0.07, 1.25]	2010
Hong,Y.2010	12	90	23	70	8.9%	0.31 [0.14, 0.69]	2010
Wang,Y.2012	7	36	15	36	4.8%	0.34 [0.12, 0.97]	2012
Wang,J.2012	4	25	7	24	2.4%	0.46 [0.12, 1.85]	2012
Xu,Y.2012	14	33	24	33	5.5%	0.28 [0.10, 0.77]	2012
Zhang,Y. 2012	6	41	11	42	3.7%	0.48 [0.16, 1.46]	2012
Xu, H.2013	4	38	10	42	3.4%	0.38 [0.11, 1.32]	2013
Cheng, B.2014	9	49	14	52	4.4%	0.61 [0.24, 1.58]	2014
Li, J.2014	3	27	2	27	0.7%	1.56 [0.24, 10.19]	2014
Liu,Y.2014	26	43	28	43	4.4%	0.82 [0.34, 1.97]	2014
Han, R.2015	2	36	4	36	1.5%	0.47 [0.08, 2.75]	2015
Zhu, H.2015	5	21	15	21	4.5%	0.13 [0.03, 0.50]	2015
Zhao, S.2015	2	43	4	43	1.5%	0.48 [0.08, 2.75]	2015
Ning, S.2015	7	31	9	31	2.8%	0.71 [0.23, 2.24]	2015
Fang, L.2016	7	45	15	45	5.0%	0.37 [0.13, 1.02]	2016
Ma, Y. 2016	4	33	11	35	3.7%	0.30 [0.08, 1.07]	2016
Li, J.2016	6	47	10	47	3.5%	0.54 [0.18, 1.64]	2016
Huang, W.2017	5	39	7	40	2.4%	0.69 [0.20, 2.40]	2017
Su, S.2017	1	40	2	39	0.8%	0.47 [0.04, 5.45]	2017
Zhou, D.2018	16	58	20	58	5.7%	0.72 [0.33, 1.60]	2018
Geng,K.2020	12	45	10	45	2.9%	1.27 [0.49, 3.34]	2020
Guo, X.2020	4	51	12	51	4.4%	0.28 [0.08, 0.93]	2020
Tan, H.2020	34	60	46	60	7.9%	0.40 [0.18, 0.87]	2020
Xu,Z.2020	1	40	5	40	1.9%	0.18 [0.02, 1.61]	2020
Total (95% CI)		1181		1156	100.0%	0.48 [0.39, 0.59]	
Total events	286		409				

Heterogeneity: Chi² = 23.48, df = 27 (P = 0.66); I² = 0%
Test for overall effect: Z = 6.85 (P < 0.00001)

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

Figure S27 The analysis of thrombocytopenia between the two groups

Study or Subgroup	Aidi injection Events	Total	Gemcitabine and cisplatin Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI	Year
Wang,Y.2009	5	32	5	27	4.5%	0.81 [0.21, 3.18]	2009
Cheng, B.2014	44	49	43	52	4.2%	1.84 [0.57, 5.94]	2014
Li, J.2014	1	27	4	27	3.8%	0.22 [0.02, 2.12]	2014
Li, X.2015	15	20	16	20	3.9%	0.75 [0.17, 3.33]	2015
Zhao, S.2015	0	43	1	43	1.5%	0.33 [0.01, 8.22]	2015
Li, J.-c.2016	7	35	16	35	12.6%	0.30 [0.10, 0.86]	2016
Ma, M.2017	10	42	14	42	10.5%	0.63 [0.24, 1.63]	2017
Wu, T.2017	6	67	15	68	13.3%	0.35 [0.13, 0.96]	2017
Wu, Y.2017	20	109	23	109	18.5%	0.84 [0.43, 1.64]	2017
Zhang, H.2018	7	40	15	40	12.2%	0.35 [0.13, 1.00]	2018
Tan, H.2020	41	60	48	60	15.0%	0.54 [0.23, 1.24]	2020
Total (95% CI)		524		523	100.0%	0.59 [0.43, 0.80]	
Total events	156		200				

Heterogeneity: Chi² = 9.52, df = 10 (P = 0.48); I² = 0%
Test for overall effect: Z = 3.32 (P = 0.0009)

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

Figure S28 The analysis of anemia between the two groups

Study or Subgroup	Aidi injection Events	Total	Gemcitabine and cisplatin Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI	Year
Zou,Y.2006	32	42	29	39	1.2%	1.10 [0.40, 3.03]	2006
Feng,X.2008	55	68	54	62	1.9%	0.63 [0.24, 1.63]	2008
Song,Z.2009	10	30	11	30	1.3%	0.86 [0.30, 2.50]	2009
Wang,Y.2009	5	32	5	27	0.8%	0.81 [0.21, 3.18]	2009
Lv,D.2009	10	30	19	30	2.2%	0.29 [0.10, 0.84]	2009
Wen,K.2009	20	38	29	38	2.4%	0.34 [0.13, 0.92]	2009
Zhang, L.2009	11	32	20	31	2.3%	0.29 [0.10, 0.81]	2009
Hou,A.2010	5	40	12	38	1.8%	0.31 [0.10, 0.99]	2010
Li,Z.2010	16	36	20	36	1.9%	0.64 [0.25, 1.62]	2010
Liu,Y.2010	7	32	14	32	1.9%	0.36 [0.12, 1.07]	2010
Hong,Y.2010	20	90	29	70	4.4%	0.40 [0.20, 0.80]	2010
Shi,X.2010	12	28	20	28	2.0%	0.30 [0.10, 0.91]	2010
Lu,Z.2011	10	34	19	34	2.3%	0.33 [0.12, 0.90]	2011
He,W.2011	12	29	13	23	1.5%	0.54 [0.18, 1.64]	2011
Sun,J.2012	28	34	29	34	0.9%	0.80 [0.22, 2.94]	2012
Wang,Y.2012	21	36	28	36	2.0%	0.40 [0.14, 1.12]	2012
Xu,Y.2012	7	33	18	33	2.4%	0.22 [0.08, 0.66]	2012
Wang,J.2012	5	25	8	24	1.1%	0.50 [0.14, 1.83]	2012
Zhang,Y. 2012	9	41	14	42	1.9%	0.56 [0.21, 1.50]	2012
Cai,H.2013	6	19	8	19	0.9%	0.63 [0.17, 2.40]	2013
Xu, H.2013	20	38	30	42	2.3%	0.44 [0.18, 1.12]	2013
Ju,S.2013	13	34	14	34	1.5%	0.88 [0.33, 2.34]	2013
Lai,L.2013	20	70	28	70	3.4%	0.60 [0.30, 1.21]	2013
Li, H.2014	18	30	22	30	1.5%	0.55 [0.18, 1.62]	2014
Cheng, B.2014	7	49	7	52	1.0%	1.07 [0.35, 3.31]	2014
Wen, H.2014	23	45	39	45	3.3%	0.16 [0.06, 0.45]	2014
Liu,Y.2014	24	43	32	43	2.4%	0.43 [0.17, 1.08]	2014
Ning, S.2015	12	31	16	31	1.7%	0.59 [0.22, 1.62]	2015
Li, X.2015	15	20	15	20	0.6%	1.00 [0.24, 4.18]	2015
Zhu, H.2015	7	21	16	21	1.8%	0.16 [0.04, 0.60]	2015
Zhao, S.2015	5	43	10	43	1.5%	0.43 [0.13, 1.40]	2015
Zhang, M.2015	32	39	27	32	0.9%	0.85 [0.24, 2.97]	2015
Zhang, S.2016	2	19	3	19	0.5%	0.63 [0.09, 4.26]	2016
Fang, L.2016	6	45	14	45	2.1%	0.34 [0.12, 0.99]	2016
Li, J.2016	15	47	27	47	3.2%	0.35 [0.15, 0.81]	2016
Ma, Y. 2016	5	33	13	35	1.8%	0.30 [0.09, 0.98]	2016
Li, J.-c.2016	7	35	19	35	2.6%	0.21 [0.07, 0.61]	2016
Su, S.2017	4	40	3	39	0.5%	1.33 [0.28, 6.39]	2017
Zhang, H.2017	16	52	29	52	3.4%	0.35 [0.16, 0.79]	2017
Wu, Y.2017	37	109	63	109	7.1%	0.38 [0.22, 0.65]	2017
Wu, T.2017	11	67	23	68	3.3%	0.38 [0.17, 0.87]	2017
Zhang, H.2018	7	40	18	40	2.5%	0.26 [0.09, 0.72]	2018
Zhou, D.2018	29	58	31	58	2.7%	0.87 [0.42, 1.81]	2018
Su,D.2019	5	41	15	41	2.3%	0.24 [0.08, 0.75]	2019
Geng,K.2020	21	45	30	45	2.7%	0.44 [0.19, 1.03]	2020
Guo, X.2020	5	51	13	51	2.0%	0.32 [0.10, 0.97]	2020
Tan, H.2020	47	60	54	60	2.0%	0.40 [0.14, 1.14]	2020
Chen,C.2020	40	49	42	49	1.3%	0.74 [0.25, 2.18]	2020
Xu,Z.2020	2	40	7	40	1.1%	0.25 [0.05, 1.28]	2020
Total (95% CI)		2043		2002	100.0%	0.45 [0.39, 0.51]	
Total events	756		1059				

Heterogeneity: Chi² = 38.98, df = 48 (P = 0.82); I² = 0%
Test for overall effect: Z = 11.21 (P < 0.00001)

Favours[Aidi injection]   Favours[Gemcitabine and cisplatin]

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

**Figure S29 The analysis of gastrointestinal toxicity between the two groups**

Study or Subgroup	Aidi injection Events	Total	Gemcitabine and cisplatin Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI	Year
Wen,K.2009	4	38	6	38	2.3%	0.63 [0.16, 2.43]	2009
Wang,Y.2009	2	32	1	27	0.4%	1.73 [0.15, 20.23]	2009
Hou,A.2010	1	40	1	38	0.4%	0.95 [0.06, 15.73]	2010
Hong,Y.2010	8	90	12	70	5.3%	0.47 [0.18, 1.23]	2010
Wang,J.2012	5	25	5	24	1.8%	0.95 [0.24, 3.81]	2012
Sun,J.2012	6	34	7	34	2.5%	0.83 [0.25, 2.78]	2012
Wang,Y.2012	5	36	7	36	2.6%	0.67 [0.19, 2.34]	2012
Zhang,Y. 2012	8	41	9	42	3.1%	0.89 [0.31, 2.59]	2012
Cheng, B.2014	8	49	12	52	4.2%	0.65 [0.24, 1.76]	2014
Li, H.2014	7	30	9	30	3.0%	0.71 [0.22, 2.25]	2014
Wen, H.2014	11	45	18	45	5.9%	0.49 [0.20, 1.20]	2014
Liu,Y.2014	8	43	9	43	3.2%	0.86 [0.30, 2.50]	2014
Zhu, H.2015	4	21	3	21	1.1%	1.41 [0.27, 7.26]	2015
Zhang, M.2015	7	39	7	32	2.7%	0.78 [0.24, 2.52]	2015
Han, R.2015	3	36	5	36	2.0%	0.56 [0.12, 2.56]	2015
Li, X.2015	12	20	15	20	2.6%	0.50 [0.13, 1.93]	2015
Zhang, S.2016	1	19	1	19	0.4%	1.00 [0.06, 17.25]	2016
Ma, Y. 2016	2	33	8	35	3.2%	0.22 [0.04, 1.11]	2016
Wu, Y.2017	10	109	32	109	12.6%	0.24 [0.11, 0.52]	2017
Zhang, H.2017	2	52	7	52	2.9%	0.26 [0.05, 1.30]	2017
Ma, M.2017	9	42	13	42	4.4%	0.61 [0.23, 1.63]	2017
Wu, T.2017	6	67	16	68	6.3%	0.32 [0.12, 0.88]	2017
Huang, W.2017	4	39	5	40	1.9%	0.80 [0.20, 3.23]	2017
Zhou, D.2018	4	58	8	58	3.2%	0.46 [0.13, 1.63]	2018
Su,D.2019	3	41	11	41	4.4%	0.22 [0.06, 0.84]	2019
Geng,K.2020	16	45	13	45	3.6%	1.36 [0.56, 3.30]	2020
Guo, X.2020	5	51	7	51	2.7%	0.68 [0.20, 2.31]	2020
Chen,C.2020	9	49	10	49	3.5%	0.88 [0.32, 2.39]	2020
Tan, H.2020	22	60	28	60	7.7%	0.66 [0.32, 1.37]	2020
Total (95% CI)		1284		1257	100.0%	0.58 [0.47, 0.72]	
Total events	192		285				

Heterogeneity: Chi² = 20.28, df = 28 (P = 0.85); I² = 0%
Test for overall effect: Z = 5.01 (P < 0.00001)

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

Figure S30 The analysis of liver toxicity between the two groups

Study or Subgroup	Aidi injection Events	Total	Gemcitabine and cisplatin Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI	Year
Wang,Y.2009	0	32	0	27		Not estimable	2009
Wen,K.2009	2	38	4	38	2.4%	0.47 [0.08, 2.75]	2009
Hong,Y.2010	4	90	7	70	4.7%	0.42 [0.12, 1.49]	2010
Sun,J.2012	3	34	4	34	2.3%	0.73 [0.15, 3.52]	2012
Wang,J.2012	4	25	4	24	2.1%	0.95 [0.21, 4.33]	2012
Zhang,Y. 2012	5	41	6	42	3.2%	0.83 [0.23, 2.98]	2012
Liu,Y.2014	8	43	9	43	4.6%	0.86 [0.30, 2.50]	2014
Wen, H.2014	4	45	6	45	3.4%	0.63 [0.17, 2.42]	2014
Cheng, B.2014	3	49	6	52	3.4%	0.50 [0.12, 2.12]	2014
Li, H.2014	7	30	9	30	4.3%	0.71 [0.22, 2.25]	2014
Li, X.2015	6	20	5	20	2.2%	1.29 [0.32, 5.17]	2015
Han, R.2015	3	36	5	36	2.9%	0.56 [0.12, 2.56]	2015
Zhu, H.2015	3	21	5	21	2.7%	0.53 [0.11, 2.59]	2015
Zhang, M.2015	3	39	4	32	2.5%	0.58 [0.12, 2.82]	2015
Ma, Y. 2016	1	33	7	35	4.1%	0.13 [0.01, 1.08]	2016
Wu, Y.2017	13	109	30	109	16.5%	0.36 [0.17, 0.73]	2017
Ma, M.2017	9	42	13	42	6.4%	0.61 [0.23, 1.63]	2017
Huang, W.2017	4	39	5	40	2.8%	0.80 [0.20, 3.23]	2017
Zhou, D.2018	4	58	8	58	4.6%	0.46 [0.13, 1.63]	2018
Su,D.2019	1	41	4	41	2.4%	0.23 [0.02, 2.16]	2019
Geng,K.2020	16	45	13	45	5.2%	1.36 [0.56, 3.30]	2020
Chen,C.2020	4	49	6	49	3.4%	0.64 [0.17, 2.41]	2020
Tan, H.2020	21	60	27	60	11.0%	0.66 [0.32, 1.37]	2020
Guo, X.2020	4	51	5	51	2.9%	0.78 [0.20, 3.10]	2020
Total (95% CI)		1070		1044	100.0%	0.62 [0.48, 0.79]	
Total events	132		192				

Heterogeneity: Chi² = 11.28, df = 22 (P = 0.97); I² = 0%
Test for overall effect: Z = 3.81 (P = 0.0001)

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

Figure S31 The analysis of renal toxicity between the two groups

Figure S32 The analysis of alopecia between the two groups

Figure S33 The analysis of neurotoxicity between the two groups

Figure S34 The analysis of oral mucositis between the two groups